Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A special protocol assessment was "unnecessary" for Phase III trials of Point Therapeutics’ oncologic talabostat given the availability of "clear guidance" on cancer trial endpoints from FDA, Chief Development Officer Margaret Uprichard told a clinical update teleconference Jan. 31.